COAG

NASDAQ 已收盘

Hemab Therapeutics Holdings

39.86 USD
▲+0.71+1.81%
盘后 39.30 -1.40%
2026-11-19
市值
$1.84B
市盈率
—
EPS
-4.72
股息率
—
52 周区间
23.00 – 55.42
成交量
248.30K
Beta
—
目标价
63.00
52W 低 23.0052W 高 55.42
价格走势

公司简介

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale...